Versant Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

Versant Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.9K	Buy	593 +80	+16%	+$2.18K	﹤0.01%	2102
2026 Q2	$13.8K	Hold	513	–	–	﹤0.01%	2110
2026 Q1	$13.9K	Hold	513	–	–	﹤0.01%	1989
2025 Q4	$18.6K	Hold	513	–	–	﹤0.01%	1687
2025 Q3	$19.5K	Hold	513	–	–	﹤0.01%	1593
2025 Q2	$6.94K	Buy	513 +82	+19%	+$1.19K	﹤0.01%	2051
2025 Q1	$6.84K	Buy	431 +378	+713%	+$4.35K	﹤0.01%	1909
2024 Q4	$652	Sell	53 -10	-16%	-$131	﹤0.01%	2250
2024 Q3	$763	Hold	63	–	–	﹤0.01%	1802
2024 Q2	$737	Hold	63	–	–	﹤0.01%	1730
2024 Q1	$813	Hold	63	–	–	﹤0.01%	1588
2023 Q4	$542	Buy	+63	New	+$495	﹤0.01%	1659
2023 Q3	–	Sell	-32	Closed	-$546	–	2009
2023 Q2	$546	Buy	+32	New	+$478	﹤0.01%	1814

Other funds holding MLYS

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return

Versant Capital Management's MLYS Position: Q3 2026 in Review

Versant Capital Management increased its Mineralys Therapeutics (MLYS) stake by 16% in Q3 2026, buying an estimated $2.18K and bringing the position to 593 shares worth $14.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2102.

Versant Capital Management first reported a position in MLYS in Q2 2023 and has held it in 13 quarters since. The position peaked at $19.5K in Q3 2025. 2 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

Versant Capital Management held 593 shares of Mineralys Therapeutics worth $14.9K as of Q3 2026.
Versant Capital Management bought 80 Mineralys Therapeutics shares in Q3 2026, an estimated $2.18K.
Mineralys Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2102 holding.
Versant Capital Management first reported a position in Mineralys Therapeutics in Q2 2023 and has held it in 13 quarters since.
Versant Capital Management's Mineralys Therapeutics position peaked at $19.5K in Q3 2025.
2 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.